What isIpamorelinFDA Status, Evidence and Risks (2026)

What ipamorelin is

Ipamorelin is a synthetic peptide made of 5 amino acids. Two of them are unnatural amino acids, ones the body does not make ³.

It acts on the ghrelin receptor, also called the growth hormone secretagogue receptor. Ghrelin is best known as a hunger hormone. Its receptor on the pituitary can also cue growth hormone release ³.

In 1998, lab and animal work described ipamorelin as the first "selective" growth hormone secretagogue. In those tests it raised growth hormone without raising several other pituitary hormones ⁴. Those were lab and animal tests only.

It was tested as a drug for slow gut recovery after surgery. FDA's 2024 briefing notes that development was discontinued after disappointing results ³.

Where FDA stands

1. Sept 29, 2023: added to FDA's Category 2 list, the substances FDA says "may present significant safety risks" in compounding ¹.
2. Sept 2024: taken off the pharmacy (503A) Category 2 list after its nomination was withdrawn ⁵.
3. Oct 29, 2024: FDA told its compounding advisory committee the evaluation criteria "weigh against" adding ipamorelin to the 503A bulks list ³. The committee voted 0 yes, 12 no, 1 abstention, for both the free base and the acetate form ².
4. Today: still on Category 2 under FDA's outsourcing facility (503B) policy ¹. Not on the 503A bulks list. Not approved by FDA for any use.

Coming off one list did not make it allowed. Are peptides legal? explains why.

Not in the HHS policy. On Oct 28, 2026, HHS filed an interim enforcement discretion policy for compounding six peptides: BPC-157, TB-500, MOTS-c, epitalon, semax and KPV ⁶. Ipamorelin is not one of them, so its status above stands, as of Oct 29, 2026. The FDA Peptide Tracker logs every change.

What the research shows

FDA also noted these gaps:

• FDA found no data supporting ipamorelin's effectiveness for growth hormone deficiency or slow gut recovery, the two uses it reviewed ³.
• FDA found no data for injection under the skin, the route proposed for compounding and the way it is usually sold ³.
• The healthy-volunteer study used men with normal pituitary function, so FDA notes its results may not apply to people with growth hormone deficiency ³.

A rise in growth hormone on a lab test shows the drug acts. It does not show a health benefit.

Side effects and FDA's concerns

FDA's stated concerns, from its Category 2 page ¹:

• Immune reactions. Possible immunogenicity "due to the potential for aggregation or peptide-related impurities."
• Hard to characterize. The unnatural amino acids "add to the complexity of peptide characterization."
• Serious events. A published study "identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility."
• Unknown routes. FDA has no safety information for some other injectable routes, so it "lacks sufficient information to know whether the drug would cause harm."

From FDA's 2024 briefing ³:

• The certificates of analysis submitted showed no testing for impurities, aggregates or endotoxin.
• The free base barely dissolves in water. FDA said the proposed 2 mg/mL injection would be "impossible to formulate."
• FDA found no repeat-dose, genotoxicity or cancer studies.
• Drugs acting on the ghrelin pathway may have "behavioral reinforcing properties," which FDA flagged as an abuse concern.
• FDA's adverse event database held 2 non-serious reports through Sept 30, 2023: tearing and headache with a compounded nasal spray, and joint pain with a compounded combination injection that could not be pinned on ipamorelin.

Side effect lists you see online usually come from sellers. We left out anything we could not source.

Why it's sold online anyway

Ipamorelin is easy to find on sites that label it "research use only" or "not for human consumption." That label is the seller saying the product is not for people.

No prescriber reviews your health history. No licensed pharmacy compounds it for one patient or checks it for human use.

FDA's concerns about impurities and aggregation are exactly the things a research-grade vial is not tested for. Prescription vs Research Peptides has more.

The CJC-1295 "stack"

Ipamorelin is often sold paired with CJC-1295, a long-acting GHRH analog. A stack has no status of its own. Each peptide keeps its own record, and FDA's advisory committee voted against both for the 503A list ^2,8. We found no published trial of the pair.

GHRP-6, another growth hormone secretagogue, sits on Category 2 for outsourcing facilities too ¹.

Sermorelin is a different peptide that acts on the GHRH receptor instead. Sermorelin vs Ipamorelin compares the two.

Asked a lot.

The sources.

1. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of Apr 22, 2026). Read it
2. FDA. Pharmacy Compounding Advisory Committee, Oct 29, 2024, meeting minutes. Read it
3. FDA. Pharmacy Compounding Advisory Committee, Oct 29, 2024, briefing document: ipamorelin (summarizes Gobburu et al. 1999 and Beck et al. 2014). Read it
4. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
5. Reed Smith. FDA removes certain peptide bulk drug substances from Category 2 (2024). Read it
6. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Docket HHS-OASH-2026-0496, FR Doc 2026-22192 (filed for public inspection Oct 28, 2026; scheduled to publish in the Federal Register Oct 30, 2026). Read it
7. Beck DE, et al. Ghrelin mimetic ipamorelin for postoperative ileus in bowel resection patients, a randomized controlled trial. Int J Colorectal Dis. 2014. Read it
8. FDA. Pharmacy Compounding Advisory Committee, Dec 4, 2024, voting results. Read it